Speaker
Prof. J.W.F. (James) Catto
Authors
Catto J.W.F.1, Kelly J.D.2, Khetrapal P.2, Ambler G.3, Ricciardi F.3, Khan S.4, Feber A.2, Dixon S.5, Williams N.6, Ahmed I.7, Charlesworth P.8, Cumberbatch M.1, Hussain S.1, Noon A.1, Kotwal S.9, Koupparis A.10, Rowe E.10, Mcgrath J.11, Vasdev N.V.12, Brew-Graves C.6, Hagan D.6, iROC Trial study group13
Institutions
1University of Sheffield, Dept. of Oncology, Sheffield, United Kingdom, 2University College London, Division of Surgery & Interventional Science, London, United Kingdom, 3University College London, Dept. of Statistical Science, London, United Kingdom, 4Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 5University of Sheffield, ScHARR, Sheffield, United Kingdom, 6University College London, Surgical & Interventional Trials Unit (SITU), Division of Surgery & Interventional Science, London, United Kingdom, 7CRUK Beatson Institute, University of Glasgow, Glasgow, United Kingdom, 8Royal Berkshire NHS Foundation Trust, Dept. of Urology, Reading, United Kingdom, 9Leeds Teaching Hospitals NHS Trust, Dept. of Urology, St. James University Hospital, Leeds, United Kingdom, 10North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, 11Royal Devon and Exeter NHS Trust, Dept. of Urology, Exeter, United Kingdom, 12Lister Hospital, Hertfordshire and Bedfordshire Urological Cancer Centre, Stevenage, United Kingdom, 13London, United Kingdom
Event
37th Annual EAU Congress
Date – Time -
Location
03 July 2022, 14:00
-
15:30,
Yellow Area, Room Forum
Session
Abstract Session 41 -
Bladder cancer radical therapy, surgery and QOL impact
Topic
Urothelial Cancer, MIBC - Treatment, Surgical